Enanta Pharmaceuticals, Inc.
Heterocyclic compounds as RSV inhibitors

Last updated:

Abstract:

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: ##STR00001## which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Status:
Grant
Type:

Utility

Filling date:

10 Apr 2019

Issue date:

13 Apr 2021